W
William J. Steinbach
High Impact
Chair and Associate Dean
faculty
Pediatrics, College of Medicine
68 h-index
286 pubs
26,472 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
William J. Steinbach leads a multidisciplinary clinical care and research program focused on immunosuppressed children, with a particular emphasis on invasive fungal infections. His work investigates the pathogenesis, diagnosis, and treatment of these infections, alongside broader efforts addressing all infections in immunocompromised patients. Dr. Steinbach has a long history of NIH funding, including multiple concurrent R01 awards and T32 awards in molecular mycology and pediatric infectious diseases. He also has experience leading national scientific and research advisory panels.
Prior to his current roles as Chair of Pediatrics and Associate Dean for Child Health at the University of Arkansas for Medical Sciences, Dr. Steinbach held distinguished professorships and leadership positions at Duke University. His research utilizes molecular, translational, and clinical approaches to understand and combat fungal infections. His scholarly output includes 286 publications with over 26,000 citations, and he maintains an h-index of 68, reflecting significant contributions to his field. His recent publications address topics such as novel antifungal agents, pharmacokinetics of antifungals in pediatric patients, and biomarkers for invasive candidiasis.
Metrics
- h-index: 68
- Publications: 286
- Citations: 26,472
Selected Publications
-
Drugs for Parasitic Infections (2025)
-
New Approaches and a Call to Action (2025)
-
Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi (2024)
-
Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network (2024)
-
Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi (2024)
-
Fecal Microbiota Transplantation: Information for the Pediatrician (2023)
-
Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal (2023)
-
Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i> (2023)
-
Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network (2023)
-
Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22 modified FK520 analog against <i>C. neoformans</i> (2023)
-
American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients (2023)
-
Calcineurin Inhibitor CN585 Exhibits Off-Target Effects in the Human Fungal Pathogen Aspergillus fumigatus (2022)
-
Prospective Evaluation of the Fungitell® (1→3) <scp>Beta‐D‐Glucan</scp> Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children's Oncology Group (2022)
Collaboration Network
Top Collaborators
Praveen R. Juvvadi
11 shared publications
- Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit <i>In Vivo</i> Therapeutic Efficacy against Cryptococcus
- <i>In Vitro</i> Activity of APX2041, a New Gwt1 Inhibitor, and <i>In Vivo</i> Efficacy of the Prodrug APX2104 against Aspergillus fumigatus
- Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against Cryptococcus
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i>
Showing 5 of 11 shared publications
Theoklis E. Zaoutis
Children's Hospital of Philadelphia (US)
7 shared publications
- Policy Statement: Antibiotic Stewardship in Pediatrics
- Policy Statement: Antibiotic Stewardship in Pediatrics
- Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents
- Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents
- Prospective Evaluation of the Fungitell® (1→3) <scp>Beta‐D‐Glucan</scp> Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children's Oncology Group
Showing 5 of 7 shared publications
Maria Ciofani
Duke University Hospital (US)
7 shared publications
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit <i>In Vivo</i> Therapeutic Efficacy against Cryptococcus
- Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against Cryptococcus
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i>
- Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi
- Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents
Showing 5 of 7 shared publications
Joseph Heitman
Duke Medical Center (US)
7 shared publications
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit <i>In Vivo</i> Therapeutic Efficacy against Cryptococcus
- Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against Cryptococcus
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i>
- Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi
- Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents
Showing 5 of 7 shared publications
Eunchong Park
Duke Medical Center (US)
6 shared publications
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit <i>In Vivo</i> Therapeutic Efficacy against Cryptococcus
- Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against Cryptococcus
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i>
- Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22 modified FK520 analog against <i>C. neoformans</i>
Showing 5 of 6 shared publications
Jiyong Hong
Duke University Hospital (US)
6 shared publications
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit <i>In Vivo</i> Therapeutic Efficacy against Cryptococcus
- Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against Cryptococcus
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i>
- Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22 modified FK520 analog against <i>C. neoformans</i>
Showing 5 of 6 shared publications
Jeffrey S. Gerber
5 shared publications
- Policy Statement: Antibiotic Stewardship in Pediatrics
- Policy Statement: Antibiotic Stewardship in Pediatrics
- COVID-19 Vaccines in Children and Adolescents
- Fecal Microbiota Transplantation: Information for the Pediatrician
- Recommended Childhood and Adolescent Immunization Schedule: United States, 2021
Sean T. O’Leary
5 shared publications
- Policy Statement: Antibiotic Stewardship in Pediatrics
- Policy Statement: Antibiotic Stewardship in Pediatrics
- COVID-19 Vaccines in Children and Adolescents
- Fecal Microbiota Transplantation: Information for the Pediatrician
- Recommended Childhood and Adolescent Immunization Schedule: United States, 2021
Dawn Nolt
Oregon Health & Science University (US)
5 shared publications
- Policy Statement: Antibiotic Stewardship in Pediatrics
- COVID-19 Vaccines in Children and Adolescents
- Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
- Recommended Childhood and Adolescent Immunization Schedule: United States, 2021
- Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
Lara Danziger‐Isakov
Cincinnati Children's Hospital Medical Center (US)
5 shared publications
- Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
- Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents
- Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents
- Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
- Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
Dwight E. Yin
University of Missouri–Kansas City (US)
5 shared publications
- Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
- Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents
- Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents
- Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
- Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
Deborah Cole
Duke Medical Center (US)
5 shared publications
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit <i>In Vivo</i> Therapeutic Efficacy against Cryptococcus
- <i>In Vitro</i> Activity of APX2041, a New Gwt1 Inhibitor, and <i>In Vivo</i> Efficacy of the Prodrug APX2104 against Aspergillus fumigatus
- Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against Cryptococcus
- Calcineurin Inhibitor CN585 Exhibits Off-Target Effects in the Human Fungal Pathogen Aspergillus fumigatus
- Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents
Craig L K Boge
Children's Hospital of Philadelphia (US)
5 shared publications
- Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents
- Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents
- Prospective Evaluation of the Fungitell® (1→3) <scp>Beta‐D‐Glucan</scp> Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children's Oncology Group
- Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
- Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network
Michael J. Hoy
Duke Medical Center (US)
5 shared publications
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit <i>In Vivo</i> Therapeutic Efficacy against Cryptococcus
- Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against Cryptococcus
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i>
- Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22 modified FK520 analog against <i>C. neoformans</i>
Anna Floyd Averette
Duke University Hospital (US)
5 shared publications
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22-modified FK520 analog against <i>C. neoformans</i>
- Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi
- Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents
- Enhanced fungal specificity and <i>in vivo</i> therapeutic efficacy of a C-22 modified FK520 analog against <i>C. neoformans</i>
- Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi
Similar Researchers
Based on overlapping research topics
Deepak Bhat
University of Arkansas at Fayetteville
Microbial infections and disease research
Child and Adolescent Health
Pharmacological Effects and Toxicity Studies
Maria Garcia Fernandez
University of Arkansas for Medical Sciences
Microbial infections and disease research
Child and Adolescent Health
Immune Response and Inflammation
Lyndsay Fisher
University of Arkansas for Medical Sciences
Microbial infections and disease research
Child and Adolescent Health
Immune Response and Inflammation
Nancy Cruz
University of Arkansas for Medical Sciences
Microbial infections and disease research
Immune Response and Inflammation
Disease Mechanisms Research
Stacie M. Jones
University of Arkansas for Medical Sciences
Microbial infections and disease research
Immune Response and Inflammation
Disease Mechanisms Research
C. Sheehy
University of Arkansas for Medical Sciences
Child and Adolescent Health
Immune Response and Inflammation
Disease Mechanisms Research